Search

Corvus Pharmaceuticals Inc

Atidarymo kaina

10.46 0.77

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.29

Max

10.79

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-4.3M

-18M

Pelnas, tenkantis vienai akcijai

-0.19

Darbuotojai

37

EBITDA

-5.3M

-17M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+182.3% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-03

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-245M

879M

Ankstesnė atidarymo kaina

9.69

Ankstesnė uždarymo kaina

10.46

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-10-27 23:56; UTC

Rithm Capital Corp. showed little change in after-market hours, trading lower since Tuesday's close, while remaining above its 20-day moving average.

2026-10-27 23:56; UTC

CDW Corporation shares declined in after-market trading, marking a third consecutive session of losses, despite broader market activity and rising durable goods orders in September.

2026-10-27 23:56; UTC

News

Rosenblatt downgraded OneSpan Inc. to Neutral while maintaining a price target of $18, contributing to a decline in after-market trading.

2026-10-27 23:56; UTC

Norwood Financial Corp's shares have declined in after-market trading, moving lower since Tuesday's close.

2026-10-27 23:56; UTC

NextDecade Corporation's shares traded roughly flat during after-market hours on Tuesday, initially showing a slight uptick before retracing to a modest gain.

2026-10-27 23:56; UTC

Waters Corp shares traded modestly lower in after-market hours, dipping nearly 1% below Tuesday's close before a slight recovery.

2026-10-27 23:56; UTC

Correlated Moves

Modine Manufacturing Company shares are modestly higher in after-market hours, coinciding with a significant rise in Ultra Clean Holdings following strong third-quarter results.

2026-10-27 23:56; UTC

Equinix, Inc. shares are modestly higher in after-market trading, continuing a trend of four consecutive sessions of gains amid rising durable goods orders.

2026-10-27 23:56; UTC

Lemonade Inc. traded modestly higher during after-market hours on Tuesday, increasing from a low point shortly after the regular session ended.

2026-10-27 23:52; UTC

Mexican Business Confidence Survey Set for Release Amid Ongoing Economic Challenges and Mixed Investor Sentiment

2026-10-27 23:52; UTC

Brazil's Central Bank faces pressure to maintain SELIC at 13.25% amid market fears of higher borrowing costs post-election, prompting downgrades in financial sector ratings.

2026-10-27 23:52; UTC

Australia's Building Permits MoM report on November 2, 2026, expected to reflect cautious market sentiment amid recent volatility and rising borrowing costs.

2026-10-27 23:52; UTC

South Korea's S&P Global Manufacturing PMI release on November 2 sparks cautious optimism amid mixed market sentiment and strong GDP growth.

2026-10-27 23:52; UTC

News

Morgan Stanley shares rose in after-market trading as the firm was named a lead underwriter for Anthropic's upcoming IPO, alongside Goldman Sachs.

2026-10-27 23:51; UTC

Lyft, Inc. shares are modestly higher in after-market trading, peaking before retracing slightly, while remaining above their 20-day moving average.

2026-10-27 23:51; UTC

ACCO Brands Corp is advancing in after-market trading, reflecting strength as it trades near the upper end of its one-month range.

2026-10-27 23:51; UTC

APTIV PLC shares are trading lower in after-market hours, declining to just below Tuesday's close and positioned below its 20-day moving average.

2026-10-27 23:51; UTC

Correlated Moves

Zillow Group, Inc. shares are lower in after-market trading following CoStar Group's $730 million acquisition of Vexcel and disappointing Q4 guidance.

2026-10-27 23:51; UTC

Oceaneering International Inc shares declined in after-market trading, continuing a trend from Tuesday's close, amid notable volatility below its 20-day moving average.

2026-10-27 23:51; UTC

Match Group, Inc. is rising in after-market trading, advancing significantly since Tuesday's close, despite having closed lower in the previous five sessions.

2026-10-27 23:51; UTC

Intuitive Surgical, Inc. shares declined modestly in after-market trading, reversing earlier gains and reflecting a cumulative loss.

2026-10-27 23:51; UTC

Correlated Moves
Social Media

AMD shares are modestly higher in after-market hours following its $1 billion investment in Meta's equity offering and deployment of AMD EPYC processors.

2026-10-27 23:51; UTC

Altria Group Inc. is trading modestly higher in after-market hours, rebounding after three consecutive sessions of declines while remaining above its 20-day moving average.

2026-10-27 23:51; UTC

Roku, Inc. declined during after-market trading, continuing a trend with four consecutive lower finishes since Tuesday's close.

2026-10-27 23:51; UTC

Coupang, Inc. is trading modestly lower in after-market hours, dipping below Tuesday's close and remaining significantly below its 20-day moving average.

2026-10-27 23:51; UTC

Correlated Moves

Vertiv Holdings Co is higher in after-market hours, following Ultra Clean Holdings Inc's third-quarter results that showed record revenue and earnings exceeding analyst expectations.

2026-10-27 23:51; UTC

GE HealthCare Technologies Inc. shares declined modestly in after-market trading, retreating from a brief peak earlier in the session.

2026-10-27 23:51; UTC

The Progressive Corporation is trading modestly higher in after-market hours, reaching its highest point since Tuesday's close and remaining above its 20-day moving average.

2026-10-27 23:51; UTC

Terex Corporation's shares are declining in after-market trading, reflecting continued weakness and trading well below its 20-day moving average.

2026-10-27 23:51; UTC

Wingstop Inc. is trading modestly lower in after-market hours, having shifted from a nearly flat position earlier in the session.

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

182.3% į viršų

12 mėnesių prognozė

Vidutinis 29.5 USD  182.3%

Aukščiausias 33 USD

Žemiausias 27 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

4

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat